Newsletter Tool

Today’s Big News

Oct 31, 2024

The 2024 Biotech Graveyard

Amgen ghosts lung disease program after missing all 14 endpoints

AbbVie pays $65M with $1.4B chaser for options on EvolveImmune's T-cell engagers

Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff

Alnylam boots Type 2 diabetes asset from haunted house

Takeda stops phase 2 sleep apnea trial over slow enrollment

Ventus gears up for phase 2 study of potential daily oral lupus drug after passing early-stage test

Fierce Biotech Fundraising Tracker '24: Evommune secures $115M series C; Axonis advances to clinic with $115M

Featured

The 2024 Biotech Graveyard

By Gabrielle Masson

Last year, biotech shutdowns spiked. Thankfully, 2024’s numbers are a little lower, dropping from the 27 closures in 2023 to 22 this year.

Amgen ghosts lung disease program after missing all 14 endpoints

By Gabrielle Masson

Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any of the primary or secondary endpoints in a midstage study.

AbbVie pays $65M, with $1.4B chaser, for options on EvolveImmune's T-cell engagers

By Nick Paul Taylor

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from EvolveImmune.

2024 Executive Interviews at Fierce Biotech Summit and New Product Planning

Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff

By Nick Paul Taylor

Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With the trials overrunning by months, the biotech is laying off 30% of its employees—including some senior managers—and focusing all its efforts on its lead program.

Discover Turbine’s way to build avatars true to patient biology

Alnylam boots Type 2 diabetes asset from haunted house

By Gabrielle Masson

Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.

Takeda stops phase 2 sleep apnea trial over slow enrollment

By Nick Paul Taylor

Takeda has stopped a phase 2 trial of danavorexton because of slow enrollment, marking another twist in the development of a orexin-2 receptor agonist franchise that has experienced ups and downs.

Ventus gears up for phase 2 study of potential daily oral lupus drug after passing early-stage test

By Eric Sagonowsky

In a phase 1 study, VENT-03 “was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials," the company said.

Fierce Biotech Fundraising Tracker '24: Evommune secures $115M series C; Axonis advances to clinic with $115M

By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer

Welcome to Fierce Biotech's Fundraising Tracker, 2024's version.

Noninvasive brain stimulation slows Alzheimer's disease in yearlong trial

By Darren Incorvaia

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a different, noninvasive approach to treating Alzheimer’s disease.

CRO Lindus Health launches 'all-in-one' service for women’s health clinical trials

By Darren Incorvaia

The All-in-One Women's Health CRO solution provides recruitment assistance, management tools, site operation support and regulatory guidance to trial sponsors.

Amgen reaps Horizon buyout rewards in Q3 as it gears up for key biosim launches

By Zoey Becker

In the third quarter, the company's overall sales grew 23% year over year and 8% excluding contributions from its Horizon Therapeutics buyout to $8.5 billion.

Fierce podcasts

Don’t miss an episode

The pulse of the medtech industry

This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs.

Closing the menopause care gap

Where are they now? Catching up with past Fierce 15 honorees

Resources

Whitepaper

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific

eBook

Decoding the data

Need the superpowers to select the right lab equipment?

Sponsored by: PHC Corporation of North America

Whitepaper

Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies

Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects.

Communicating the Value of Biopharma Assets to Potential Investors

How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.

Presented by: Blue Matter